FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099341258> ?p ?o ?g. }

• W2099341258 endingPage "1369" @default.
• W2099341258 startingPage "1362" @default.
• W2099341258 abstract "The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and post-operative radiotherapy in patients with malignant pleural mesothelioma (with a severity of cT3N1M0 or less). Induction chemotherapy consisted of three courses of cisplatin 75 mg·m⁻² and pemetrexed 500 mg·m⁻². Nonprogressing patients underwent extrapleural pneumonectomy followed by post-operative radiotherapy (54 Gy, 30 fractions). Our primary end-point was success of treatment and our secondary end-points were toxicity, and overall and progression-free survival. 59 patients were registered, one of whom was ineligible. Subjects' median age was 57 yrs. The subjects' TNM scores were as follows: cT1, T2 and T3, 36, 16 and six patients, respectively; cN0 and N1, 57 and one patient, respectively. 55 (93%) patients received three cycles of chemotherapy with only mild toxicity. 46 (79%) patients received surgery and 42 (74%) had extrapleural pneumonectomy with a 90-day mortality of 6.5%. Post-operative radiotherapy was completed in 37 (65%) patients. Grade 3-4 toxicity persisted after 90 days in three (5.3%) patients. Median overall survival time was 18.4 months (95% CI 15.6-32.9) and median progression-free survival was 13.9 months (95% CI 10.9-17.2). Only 24 (42%) patients met the definition of success (one-sided 90% CI 0.36-1.00). Although feasible, trimodality therapy in patients with mesothelioma was not completed within the strictly defined timelines of this protocol and adjustments are necessary." @default.
• W2099341258 created "2016-06-24" @default.
• W2099341258 creator A5012634831 @default.
• W2099341258 creator A5024351266 @default.
• W2099341258 creator A5025925751 @default.
• W2099341258 creator A5033764794 @default.
• W2099341258 creator A5049735686 @default.
• W2099341258 creator A5053218448 @default.
• W2099341258 creator A5060164059 @default.
• W2099341258 creator A5072704808 @default.
• W2099341258 creator A5085722313 @default.
• W2099341258 creator A5088569850 @default.
• W2099341258 date "2010-06-04" @default.
• W2099341258 modified "2023-09-24" @default.
• W2099341258 title "Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial" @default.
• W2099341258 cites W1519231732 @default.
• W2099341258 cites W1977376622 @default.
• W2099341258 cites W1977438589 @default.
• W2099341258 cites W1979339367 @default.
• W2099341258 cites W1995748531 @default.
• W2099341258 cites W2001457568 @default.
• W2099341258 cites W2005403885 @default.
• W2099341258 cites W2018767217 @default.
• W2099341258 cites W2021219775 @default.
• W2099341258 cites W2029684228 @default.
• W2099341258 cites W2047339424 @default.
• W2099341258 cites W2054256117 @default.
• W2099341258 cites W2056385759 @default.
• W2099341258 cites W2057195752 @default.
• W2099341258 cites W2064100047 @default.
• W2099341258 cites W2092173244 @default.
• W2099341258 cites W2097851464 @default.
• W2099341258 cites W2100576484 @default.
• W2099341258 cites W2102627969 @default.
• W2099341258 cites W2105015900 @default.
• W2099341258 cites W2114441629 @default.
• W2099341258 cites W2114866480 @default.
• W2099341258 cites W2125980018 @default.
• W2099341258 cites W2129967236 @default.
• W2099341258 cites W2137222793 @default.
• W2099341258 cites W2138270921 @default.
• W2099341258 cites W2171227985 @default.
• W2099341258 doi "https://doi.org/10.1183/09031936.00039510" @default.
• W2099341258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20525721" @default.
• W2099341258 hasPublicationYear "2010" @default.
• W2099341258 type Work @default.
• W2099341258 sameAs 2099341258 @default.
• W2099341258 citedByCount "214" @default.
• W2099341258 countsByYear W20993412582012 @default.
• W2099341258 countsByYear W20993412582013 @default.
• W2099341258 countsByYear W20993412582014 @default.
• W2099341258 countsByYear W20993412582015 @default.
• W2099341258 countsByYear W20993412582016 @default.
• W2099341258 countsByYear W20993412582017 @default.
• W2099341258 countsByYear W20993412582018 @default.
• W2099341258 countsByYear W20993412582019 @default.
• W2099341258 countsByYear W20993412582020 @default.
• W2099341258 countsByYear W20993412582021 @default.
• W2099341258 countsByYear W20993412582022 @default.
• W2099341258 countsByYear W20993412582023 @default.
• W2099341258 crossrefType "journal-article" @default.
• W2099341258 hasAuthorship W2099341258A5012634831 @default.
• W2099341258 hasAuthorship W2099341258A5024351266 @default.
• W2099341258 hasAuthorship W2099341258A5025925751 @default.
• W2099341258 hasAuthorship W2099341258A5033764794 @default.
• W2099341258 hasAuthorship W2099341258A5049735686 @default.
• W2099341258 hasAuthorship W2099341258A5053218448 @default.
• W2099341258 hasAuthorship W2099341258A5060164059 @default.
• W2099341258 hasAuthorship W2099341258A5072704808 @default.
• W2099341258 hasAuthorship W2099341258A5085722313 @default.
• W2099341258 hasAuthorship W2099341258A5088569850 @default.
• W2099341258 hasBestOaLocation W20993412581 @default.
• W2099341258 hasConcept C126322002 @default.
• W2099341258 hasConcept C141071460 @default.
• W2099341258 hasConcept C142724271 @default.
• W2099341258 hasConcept C168563851 @default.
• W2099341258 hasConcept C203092338 @default.
• W2099341258 hasConcept C2776256026 @default.
• W2099341258 hasConcept C2776611710 @default.
• W2099341258 hasConcept C2776694085 @default.
• W2099341258 hasConcept C2777240266 @default.
• W2099341258 hasConcept C2777407522 @default.
• W2099341258 hasConcept C2777589429 @default.
• W2099341258 hasConcept C2778239845 @default.
• W2099341258 hasConcept C2910444461 @default.
• W2099341258 hasConcept C509974204 @default.
• W2099341258 hasConcept C71924100 @default.
• W2099341258 hasConceptScore W2099341258C126322002 @default.
• W2099341258 hasConceptScore W2099341258C141071460 @default.
• W2099341258 hasConceptScore W2099341258C142724271 @default.
• W2099341258 hasConceptScore W2099341258C168563851 @default.
• W2099341258 hasConceptScore W2099341258C203092338 @default.
• W2099341258 hasConceptScore W2099341258C2776256026 @default.
• W2099341258 hasConceptScore W2099341258C2776611710 @default.
• W2099341258 hasConceptScore W2099341258C2776694085 @default.
• W2099341258 hasConceptScore W2099341258C2777240266 @default.
• W2099341258 hasConceptScore W2099341258C2777407522 @default.
• W2099341258 hasConceptScore W2099341258C2777589429 @default.

• next